PROVIDER*Update*

CONTRACTUAL | APRIL 1, 2026 | UPDATE 26-416m | 4 PAGES

`

Medication Trend Updates and Drug List/Formulary Changes – 2nd Quarter 2026

Review drug list and medication benefit changes, and medication safety issues

Stay up to date with information about:

- FDA seeks removal of suicide warnings on GLP-1 weight loss drugs
- Changes to the Medi-Cal drug benefits for the second quarter of 2026

FDA seeks removal of suicide warnings on GLP-1 weight loss drugs

The Food and Drug Administration (FDA) requested that manufacturers of glucagon-like peptide-1 receptor agonist (GLP-1 RA) remove warnings related to suicidal ideation and behavior (SI/B) from product labeling.

The affected products include:

- Novo Nordisk's Saxenda® (liraglutide)
- Novo Nordisk's Wegovy® (semaglutide)
- Eli Lilly's Zepbound® (tirzepatide)

This request follows a comprehensive FDA review that found no increased risk of SI/B associated with GLP-1 RA use. A meta-analysis of 91 placebo-controlled trials involving 107,910 patients also showed no increased risk of psychiatric adverse events with GLP-1 medications.

Notably, GLP-1 RA products approved for the treatment of type 2 diabetes mellitus do not currently include SI/B risk information in their labeling. To ensure consistent messaging across all FDA-approved GLP-1 RA products, the FDA is requesting removal of this warning from the prescribing information for Saxenda®, Wegovy®, and Zepbound®.

Healthcare professionals should be prepared to inform patients that, based on a comprehensive review of available data, the FDA has found no increased risk of suicidal ideation or behavior associated with these medications.

THIS UPDATE APPLIES TO:

- Physicians and Practitioners
- Participating Physician Groups

PROVIDER SERVICES

CalViva Health Medi-Cal (including ECM and CS providers) – 888-893-1569

PROVIDER PORTAL

provider.healthnetcalifornia.com

Source: FDA news release at https://bit.ly/FDA_Removal_GLP-1_WeightLossDrug

Changes to Medi-Cal medication benefits

The Pharmacy Advisory Committee is made up of practicing physicians, pharmacists and other health care professionals. Every quarter, the committee reviews medication benefits for Medi-Cal members. They decide which medications stay on the same tier and which ones move to a different tier.

A table showing some of the recent changes for **Q2 2026** is available on **pages 3-4**. It includes:

- Medication names
- Their updated formulary status
- Formulary alternative options
- Notes or comments

You can find the complete list of formularies for all products, including for Medi-Cal on the Pharmacy Information for Providers page at https://bit.ly/PharmacyInformationforProviders.

For medical drug benefits, refer to the *Outpatient Pharmaceuticals (Submitted Under Medical Benefit)* section of the CalViva Health Medi-Cal Fee-for-Service **Prior Authorization List** at https://bit.ly/HealthNetPriorAuthorizations.

Pharmacy help lines

For more information regarding changes to the Medi-Cal drug list or medication benefit, contact the proper pharmacy phone number listed.

Product	Phone number	Fax number
Pharmacy Benefit (Medi-Cal Rx)	800-977-2273	800-869-4325
Medical Benefit Drugs (Medi-Cal)	800-867-6564, option #2	833-953-3436

Need help? Contact us

If you have questions regarding the information contained in this update, contact CalViva Health at 888-893-1569.

Changes to the Medi-Cal medication benefits

Note: The information in the tables is subject to change. For the most current details, please refer to the Prior Authorization List at https://bit.ly/HealthNetPriorAuthorizations.

Medication	Status	Formulary alternative(s)	Comments
Nasal preparation			
Cardamyst™ (etripamil) nasal spray	Carved out to state	Carved out to state	A calcium channel blocker indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults
Oral preparation			
Hyrnuo® (sevabertinib) tablet	Carved out to state	Carved out to state	A kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy
Komzifti™ (ziftomenib) capsule	Carved out to state	Carved out to state	A menin inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options
Kygevvi™ (doxecitine and doxribtimine) powder for oral solution	Carved out to state	Carved out to state	A combination of doxecitine and doxribtimine, both pyrimidine nucleosides, indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years
Lynkuet® (elinzanetant) capsule	Carved out to state	Carved out to state	A neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause
Myqorzo® (aficamten) film-coated tablet	Carved out to state	Carved out to state	A cardiac myosin inhibitor indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms

Changes to the Medi-Cal medication benefits, *continued*

Medication	Status	Formulary alternative(s)	Comments
Injectable preparation			
Exdensur® (depemokimab-ulaa) single-dose prefilled syringe/pen	Medical benefit[1]	Carved out to state	An interleukin-5 (IL-5) antagonist, a monoclonal antibody (humanized immunoglobulin G [IgG]1 kappa) indicated for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older
Lerochol™ (lerodalcibep-liga) single-dose prefilled syringe	Medical benefit[1]	Carved out to state	A proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH)
Waskyra™ (etuvetidigene autotemcel) suspension for intravenous use	Medical benefit[1]	Carved out to state	An autologous hematopoietic stem cell-based gene therapy indicated for the treatment of pediatric patients aged six months and older and adults with Wiskott-Aldrich Syndrome (WAS) who have a mutation in the WAS gene for whom hematopoietic stem cell transplantation (HSCT) is appropriate and no suitable human leukocyte antigen (HLA)-matched related stem cell donor is available

[1]Prior authorization is required to verify that the member is eligible and satisfies clinical protocols to ensure appropriate use of the medication.